Atopic dermatitis is a chronic inflammatory skin disease that was analyzed as an outcome in single-cell transcriptomic mendelian randomization and co-localization studies, with GWAS summary statistics integrated from FinnGen (n = 31,245) and the GWAS Catalog (n = 22,474). It is linked to immune-mediated regulatory mechanisms and potential drug targets through single cell transcriptomic mendelian randomization, and the literature highlights pathways involving nrf2 and ho 1 in experimental therapy models. Recent work also evaluated how pre-existing atopic dermatitis affects outcomes of immune checkpoint therapy, suggesting relevance beyond dermatology into oncology treatment response. A 2026 International Immunopharmacology study (PMID:41747595) used sc-eQTL, GWAS, and MR to prioritize immune-related mechanisms, while a 2026 Materials Today Bio paper (PMID:41685363) tested a microneedle-assisted dual-nano delivery platform combining JAK1 gene editing with EGCG-lactoferrin nanoparticles. Overall, the disease is being studied both as a genetically informed inflammatory phenotype and as a context for advanced delivery strategies and immunotherapy interactions.
Genetic and immune mechanisms
- Single-cell transcriptomic mendelian randomization was used to identify immune-mediated regulatory mechanisms and drug targets in atopic dermatitis. (PMID:41747595)
- The study integrated sc-eQTL, GWAS, and MR approaches, using AD GWAS summary statistics from FinnGen (n = 31,245) and GWAS Catalog (n = 22,474). (PMID:41747595)
- Co-localization analysis supported mechanistic links between genetic signals and disease-relevant immune pathways in atopic dermatitis. (PMID:41747595)
Therapeutic delivery and experimental treatment
- A combined microneedle-assisted dual-nano delivery strategy was developed for atopic dermatitis treatment. (PMID:41685363)
- The platform involved egcg and lactoferrin nanoparticles, with JAK1 gene editing via CRISPR-CasRx in a microneedle-based system. (PMID:41685363)
- In the atopic dermatitis model, therapy activated nrf2 and ho 1, except for the PBAE-plasmid NP-loaded microneedles. (PMID:41685363)
Immunotherapy outcomes
- Pre-existing atopic dermatitis was assessed for its impact on clinical outcomes of immune checkpoint therapy. (PMID:42029059)
- The study specifically examined whether baseline atopic dermatitis altered response patterns or adverse clinical outcomes during immune checkpoint treatment. (PMID:42029059)
- This extends the relevance of atopic dermatitis to cancer immunotherapy decision-making. (PMID:42029059)